Vaccine Info

Mosquirix RTSS/AS01e Malaria Vaccine

Authored by
Staff
Last reviewed
October 27, 2021
Share

Mosquirix RTS,S/AS01e Malaria Vaccine Description

GSK's Mosquirix RTS,S/AS01e, is a recombinant malaria vaccine candidate consisting of the P. falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage. Mosquirix aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host's bloodstream through a mosquito bite and infects liver cells.

The T-cell epitope of CSP is O-fucosylated in Plasmodium falciparum and Plasmodium vivax, while the RTS,S/AS01e malaria vaccine produced in yeast is not.

Mosquirix does not provide complete protection against malaria caused by P. falciparum. The malaria vaccine is designed to prevent the parasite from infecting the liver, entering the bloodstream, infecting red blood cells, leading to disease symptoms. In addition, because of the vaccine's composition, it also protects against the hepatitis B virus.

In July 2015, the European Medicines Agency gave a positive regulatory assessment of the RTS,S/AS01e malaria vaccine for 5–17-month-olds. And the WHO published a background paper.

The NEJM published the results of phase 3 clinical study sponsored by the London School of Hygiene and Tropical Medicine on September 9, 2021, that concluded: Administration of RTS,S/AS01E was noninferior to chemoprevention in preventing uncomplicated malaria. The combination of these interventions resulted in a substantially lower incidence of uncomplicated malaria, severe malaria, and death from malaria than either intervention alone.

On October 6, 2021, the WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, announced that the WHO is recommending the general use of the world's first malaria vaccine. The WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.

The WHO's malaria vaccine implementation program (MVIP) FAQs, and the PATH Washington DC Overview. The U.S. CDC published Malaria Vaccines: The Way Forward, on October 7, 2021.

GlaxoSmithKline Biologicals S.A. Mosquirix H-W-2300. GSK's commitment to people at risk of malaria is linked.

Mosquirix RTS,S/AS01e Malaria Vaccine History

The RTS,S/AS01e malaria vaccine, was developed by GSK for more than 30 years. The RTS,S vaccine was created in 1987 as part of a collaboration between GlaxoSmithKline and the Walter Reed Army Institute of Research that began in 1984.

This first-generation malaria vaccine demonstrates modest efficacy against malaria illness and holds promise as a public health tool, especially for children in high-transmission areas where mortality is high.

In partnership with PATH since 2001, GSK is currently testing the vaccine in Ghana, Kenya, and Malawi under the Malaria Vaccine Implementation Programme. Ministries of health are leading the implementation of the vaccine, which is being given to young children through the three countries' routine immunization programs, with WHO providing technical and scientific leadership, playing a coordinating role, and working in collaboration with GSK, PATH, and a range of other partners.

The first dose of the vaccine has reached more than 500,000 children since ministries of health initiated the three participating countries' pilots in 2019. The main evidence derives from a large clinical trial conducted in seven African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania), reports the EMA. Data from this trial showed that Mosquirix provides modest protection against Plasmodium falciparum malaria in children in the 12 months following vaccination. The vaccine effectively prevented a first or only clinical malaria episode in 56% of children aged between 5-17 months and in 31% of children aged 6-12 weeks. The efficacy of the vaccine decreased after one year. The safety profile of the vaccine was considered acceptable.

Since January 1, 2019, Burundi's Ministry of Health has reported nearly 6 million malaria cases (out of a total population of approximately 12 million), with more than 1,800 deaths.

WHO certification of malaria elimination, 1955–2021: Countries with at least 3 consecutive years of zero indigenous cases are eligible to apply for a WHO certification of malaria-free status.

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. Our approach to Pharmaceutical Research and Development (R&D) focuses on science related to the immune system, the use of human genetics, and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. 2020 Annual Report; For further information, please visit GSK.

Mosquirix RTS,S/AS01e Malaria Vaccine Indication

Mosquirix vaccine has been developed to prevent malaria in young children living in malaria-endemic regions. According to official recommendations in those areas, the vaccine should only be used in areas of the world where malaria caused by Plasmodium falciparum is prevalent. Plasmodium falciparum in Ancient Egypt was published by the U.S. CDC in 2008.

A recent study of variation at the C-terminal sequence, part of RTS,S, demonstrated a slightly diminished efficacy for P. falciparum strains that contain sequences heterologous to RTS,S,8 and suggests that vaccine efficacy may depend somewhat on how closely CSP in the community matches that found in the vaccine. 

In Europe, Mosquirix is currently indicated for children aged 5 to 17 months and infants aged 6 to 12 weeks at the first vaccination time to help protect against malaria caused by the parasite Plasmodium falciparum. However, Mosquirix is not approved for older children, teens, nor adults.

About 2,000 cases of malaria are diagnosed in the United States annually, mostly in returned travelers, says the U.S. CDC. Travelers to sub-Saharan Africa have the most significant risk of both getting malaria and dying from their infection. 

Vegetation coverage in this study site might be a proxy for nearness to rivers and branching, shallow wetlands called "dambos," which could serve as breeding sites for mosquitoes. We observed statistically significant modification of the efficacy of RTS,S/AS01 by forest cover, suggesting that initial vaccine efficacy and the importance of the fourth dose varies based on ecological context.

Mosquirix RTS,S/AS01e Malaria Vaccine Dosage

Mosquirix is administered as an intramuscular injection. Phase 3 studies evaluated three and four doses. The WHO says the RTS,S/AS01 malaria vaccine should be provided in a schedule of 4 doses in children from 5 months of age for the reduction of malaria disease and burden.

Mosquirix RTS,S/AS01e Malaria Vaccine Safety and Side Effects

With regard to vaccine safety, the RTS,S/AS01 profile is similar to other routine vaccines given to children except for an increased risk of febrile seizures. Children aged 5–17 months at first vaccination were more likely than controls to have a febrile seizure within 7 days after vaccination, especially the third dose. This effect was transient, and all affected children recovered after 7 days. Safety surveillance also suggested a potential increased risk of meningitis and cerebral malaria in this same age group.27 A study in Kenyan children with WHO Stage 1 or 2 HIV disease found that RTS,S/AS01 was well-tolerated in this population and that they can be safely included in future vaccination programs.

World Malaria Day

World Malaria Day 2021 coincides with the 15th anniversary of the United States President's Malaria Initiative (PMI) and follows the first anniversary of the declaration of the coronavirus disease (COVID-19) pandemic. From 2006 to the present, the PMI has led to considerable country-managed progress in malaria prevention, care, and treatment in 24 of the highest-burden countries in sub-Saharan Africa and three countries in Southeast Asia Greater Mekong subregion. Furthermore, it has contributed to a 29% reduction in malaria cases and a 60% reduction in the death rates in sub-Saharan Africa.

Mosquirix RTS,S/AS01e Malaria Vaccine News

October 14, 2021 - The Indian Express published an audio: An expert on why the malaria vaccine matters, and the reason it took so long.

October 14, 2021 - The Hill published: Malaria vaccine is a triumph for global public health.

October 8, 2021 - The journal Nature published: Scientists hail historic malaria vaccine approval — but point to challenges ahead. The WHO-approved RTS,S vaccine has modest efficacy and requires a complex regimen of doses, so ample funding and clear communication will be crucial to success.

October 7, 2021 - The National Geographic published: 'Historic moment': Why the WHO endorsed the first malaria vaccine.

October 6, 2021 - The World Health Organization announced it is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission.

October 6, 2021 - PATH applauds the World Health Organization recommending for broader use of the world's first malaria vaccine, RTS,S/AS01E (RTS,S). This historic recommendation means that the vaccine, which is currently in routine use as part of a pilot program in areas of Ghana, Kenya, and Malawi, can soon be available in other malaria-endemic nations as well.

September 9, 2021 - The NEJM journal published an ORIGINAL ARTICLE: Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. CONCLUSIONS - Administration of RTS,S/AS01E was noninferior to chemoprevention in preventing uncomplicated malaria. The combination of these interventions resulted in a substantially lower incidence of uncomplicated malaria, severe malaria, and death from malaria than either intervention alone.

August 25, 2021 - The NEJM journal published an Original Article: Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. CONCLUSIONS - Administration of RTS,S/AS01E was noninferior to chemoprevention in preventing uncomplicated malaria. The combination of these interventions resulted in a substantially lower incidence of uncomplicated malaria, severe malaria, and death from malaria than either intervention alone.

August 4, 2021 - In advance of key decisions from WHO and Gavi and to address the associated uncertainty around future demand, Gavi, GSK, and MedAccess have developed an innovative financing solution to ensure continuous manufacturing of the vaccine antigen RTS,S so that it will be immediately available should there be a positive decision to move forward.

June 30, 2021 - The WHO announced China had been awarded a malaria-free certification. "Today, we congratulate the people of China on ridding the country of malaria," said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. "Their success was hard-earned and came only after decades of targeted and sustained action. With this announcement, China joins the growing number of countries that are showing the world that a malaria-free future is a viable goal."

April 21, 2021 - The WHO announced a new initiative to halt disease transmission in 25 more countries by 2025. Of the 87 countries with malaria, 46 reported fewer than 10 000 cases of the disease in 2019 compared to 26 countries in 2000. By the end of 2020, 24 countries had reported interrupting malaria transmission for 3 years or more. Of these, 11 were certified malaria-free by WHO.

March 17, 2021 - Study: Adverse pregnancy outcomes among women presenting at antenatal clinics in Ouélessébougou, Mali. Conclusion: Low gravidity and young age predict perinatal death and PTD. The information collected here can be used as a baseline for adverse pregnancy outcomes in future vaccine trials in pregnant women.

March 12, 2021 - Review: Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?

March 1, 2021 - The U.S. CDC reported a malaria epidemic is ongoing in Burundi. Since January 1, 2019, the Ministry of Health has reported nearly 6 million cases (out of a total population of approximately 12 million), with more than 1,800 deaths.

February 25, 2021 - The WHO reported El Salvador today became the first country in Central America to be awarded a certification of malaria elimination by the World Health Organization. The certification follows more than 50 years of commitment by the Salvadoran government and people to ending the disease in a country with a dense population and geography hospitable to malaria.

January 27, 2021 - GSK, PATH, and Bharat Biotech (BBIL) announced a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine, and a license on all rights of the RTS,S/AS01 malaria vaccine to BBIL. In addition, GSK will retain the adjuvant's production (AS01E) and supply it to BBIL.

January 27, 2021 - Fighting malaria in the lab and on the ground. Malaria is one of the world's oldest diseases, with evidence of the mosquito-borne illness found in tissues from Ancient Egyptian mummies. But despite its long history and our understanding of its biology, malaria remains one of the world's deadliest diseases.

September 8, 2020 - The Nature journal published: The quest for a vaccine against malaria.

August 16, 2019 - Overcoming obstacles to end malaria. The only treatment available for this type of malaria, primaquine, needs to be taken for fourteen days, so it is often associated with poor compliance. To address this and make it easier for patients, we have been developing tafenoquine, in partnership with the not-for-profit foundation Medicines for Malaria Venture (MMV), as a single-dose treatment.

July 19, 2019 - The Lancet published an article: RTS,S malaria vaccine could provide major public health benefits.

July 15, 2021 - Product Review: RTS,S/AS01 vaccine (Mosquirix™): an overview.

August 23, 2017 - Original Research was published. RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. In conclusion, RTS,S/AS01E vaccine induces T cells of higher functional heterogeneity and polyfunctionality than previously characterized. Responses detected in memory CD4+ T cell compartments may provide correlates of RTS,S/AS01-induced immunity, and duration of protection in future correlates of immunity studies.

April 23, 2015 - The Lancet published 'Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of phase three, individually randomized, controlled trial.' Interpretation - RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3–4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures, especially in areas of high transmission. This trial is registered with ClinicalTrials.gov, number NCT00866619.

Mosquirix RTS,S/AS01e Malaria Vaccine Clinical Trials

Clinical Trial NCT03806465: An Evaluation of the Cluster-randomised Pilot Implementation of RTS,S/AS01 Through Routine Health Systems in Moderate to High Malaria Transmission Settings in Africa.

Clinical Trial: NCT04661579: The proposed trial design has been developed to answer several questions related to the nature of RTS,S vaccine efficacy in African adults that may be influenced by concurrent and/or past P. falciparum infection leading to a state of immunologic hypo-responsiveness. The proposed study design encompasses five groups. Three groups (Groups 1, 2, and 3) will be administered RTS,S/AS01E on a 0, 1, 7-month schedule with Dose 3 delivered as a 1/5th fractional dose. Two groups (Groups 4 and 5) will be administered a comparator vaccine on a 0, 1, 7-month schedule.

Clinical Trial NCT03143218: A double-blind, individual randomized phase 3 trial will be undertaken in 6000 children under the age of five years living in areas of Burkina Faso or Mali where the transmission of malaria is intense and highly seasonal to determine whether the malaria vaccine RTS,S/AS01 is (a) as effective as SMC with SP + AQ in preventing clinical malaria (b) provides additional, useful protection when given together with SMC. The primary trial end-point will be the incidence of clinical episodes of malaria detected by passive case detection. The protective efficacy of the combination as compared with the vaccine alone against these outcomes was 59.6% (95% CI, 54.7 to 64.0), 70.6% (95% CI, 42.3 to 85.0), and 75.3% (95% CI, 12.5 to 93.0), respectively.